Insilico Medicine published in the scientific journal Nature Biotechnology the results of a clinical trial of the experimental drug rentosertib, developed with the help of artificial intelligence algorithms. The medication was originally created for the treatment of chronic lung diseases and the potential extension of lifespan. However, it was precisely while testing the tablets' effect on biological markers of aging that the researchers recorded an effect that no similar drug has yet been able to demonstrate: a statistically significant slowing of biological aging in the trial participants.
How the clinical trials were conducted
The study involved 42 patients. Testing lasted 12 weeks, during which the scientists tracked the dynamics of the body's biological indicators. To assess the effect, the team used six different 'aging clocks' — specialized AI-based algorithms that determine the actual state of the body based on a combination of data: blood tests, physiological and psychological indicators. This multifactorial approach made it possible to obtain a more comprehensive picture than when relying on a single marker.
Results: six years off the biological age
By the end of the 12-week testing course, the algorithms recorded a positive trend: the participants' biological age decreased by an average of six years across the combined set of 'aging clocks' used. This is the first documented case in which an experimental drug has demonstrated the ability not merely to affect individual biomarkers, but to shift the integral assessment of a person's biological age in the direction of 'rejuvenation.' The publication of the data in Nature Biotechnology adds further weight to the results, as the journal undergoes rigorous peer review.
Contradictory data
Despite the high profile of the results, the scientific community urges a measured assessment of the methodology. The key problem is that the accuracy of the 'aging clocks' themselves — algorithms that measure chemical changes in DNA or protein levels in the blood — remains a subject of active scientific debate. There is still no single universally accepted indicator of a person's biological age in the world, which means that different models may yield diverging estimates. Some researchers warn that attempts to artificially alter aging marker readings could potentially damage the body's natural restorative functions. Thus, the interpretation of 'minus six years' as genuine rejuvenation is contested: some specialists regard it as a shift in the readings of a specific model, rather than as a proven biological effect.
Prospects and limitations
The drug rentosertib is in the early stages of development. Before it can receive official approval for use, it must undergo a lengthy series of additional trials, including expanded phases of clinical research with a larger sample size and a longer observation period. Even if the effect is confirmed at scale, questions of long-term safety and potential impact on natural regeneration mechanisms will remain central for regulatory authorities. Nevertheless, the publication in Nature Biotechnology cements rentosertib's position as the first drug for which a measurable shift in biological age has been recorded, and opens a new direction in geriatric pharmacology.
